Cullinan Therapeutics (CGEM) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.81

Estimate

-$0.85

Surprise

+4.8%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Cullinan Therapeutics (CGEM) reported a narrower loss than forecast — diluted EPS of -$0.81 against the -$0.85 estimate (a 4.8% beat on a still-unprofitable quarter).

TrendMatrix currently rates CGEM Sell at 5.5/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +4.8% surprise compares with a +9.4% four-quarter average. Next scheduled report: 2026-11-14.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$20.63

Price target

$29.18

Stop

$19.19

Upside to target

+41.4%

Reward-to-risk

4.0:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.26B

P/E (fwd)

-7.7

52-week range

$5.68–$23.19

Off 52-week high

11.0%

RSI (14)

25

Volume vs avg

1.04×

Score today

5.5/10